ערך בספרים למניה: Alterity Therapeutics (ATHE)

Alterity Therapeutics (ATHE) aims to halt cellular senescence through innovative metal binding in the brain. Diversification of the small molecule pipeline reduces regulatory risks, and patent protection will be fully established following final tests. The book value per share illustrates capital dynamics, where 1.62 reflects the latest metric value, confirming the current financial stability of the pre-commercial business.

Book value per share represents the difference between all of the issuer's assets and liabilities divided by the number of securities, which determines the actual value of the owner's stake. Analyzing the equity per share is critically important for Alterity Therapeutics (ATHE), as the lack of revenue and the risks of trial failure make this indicator the sole measure of financial stability in the face of potential bankruptcy.